Indeed, according to the European Association of Nuclear Medicine (EANM) guideline based on the reported outrider phase II trial on [177Lu]Lu-PSMA-617, the required SUVmax at dominant sites of tumor involvement should be at least 1.5-fold higher than the baseline SUVmean [68Ga]Ga-PSMA-11 of the liver for qualification for therapy [20, 21]. The gene discussed is FOLH1; the disease is neoplasm.